Las Vegas Sands Corp. vs Tilray Brands Inc — how do they compare? Las Vegas Sands Corp. trades at $45.7 (market cap $30.36B), while Tilray Brands Inc trades at $4.26 (market cap $524.07M). The key difference: Las Vegas Sands Corp. is far larger — about 57.9× Tilray Brands Inc's market cap, and Las Vegas Sands Corp. pays a 2.4% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| LVS | TLRY | |
|---|---|---|
Market Cap | $30.36B | $524.07M |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $21.00 |
52-Week Low | $44.78 | $4.23 |
Enterprise Value | $42.75B | $621.22M |
Dividend Yield | 2.4% | — |
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.66, up 0.66% on the day, with a bearish technical signal but strong fundamentals. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.91 beating expectations. Revenue growth is robust, reaching $13.02B in 2025, and profitability metrics like a 49.59% gross margin and 94.53% ROE are impressive. The company maintains positive cash flow and recently paid a $0.30 dividend. Analyst sentiment is bullish with a $65.18 consensus price target, though technical indicators suggest near-term pressure.
The outlook for LVS is positive based on fundamental strength and analyst optimism, but risks include high debt levels and bearish technical trends. Investment opportunity lies in its earnings momentum and valuation upside, while investors should monitor debt management and market volatility. The stock's current price near support levels may present a entry point if fundamentals hold.
TLRY trades at $4.23, down 1.63% with bearish technical signals. The company reported revenue growth to $821.31M in 2025 but faces severe profitability challenges with a net loss of $2.19B and negative margins. Recent expansion includes medical cannabis launches in Panama and strategic acquisitions, while analyst consensus shows cautious sentiment with 65% hold ratings.
The outlook remains challenging due to persistent losses and high debt levels, though expansion initiatives and potential regulatory changes offer long-term opportunities. Key risks include execution on profitability, competitive pressures, and cannabis regulatory uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →